1.	Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEICAM/2009-02, 2010-022689-29, NCT01298193
2.	Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Phase: Phase IV Type: Supportive care Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 110806, NCT01625455
3.	A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225 AM1) (KMEC) Phase: Phase IV Type: Supportive care Status: Active Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 0869-225, MK-0869-225, NCT01636947
4.	Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EmNa (2001-004956-38), EudraCT-No: 2004-004956-38, NCT00571168
5.	Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone Phase: Phase III Type: Supportive care Status: Active Age: 20 and over Sponsor: Other Protocol IDs: ROAD, NCT01536691
6.	Efficacy of Aprepitant (Emend®) in Children Phase: Phase III Type: Supportive care, Treatment Status: Approved-not yet active Age: 20 and under Sponsor: Other Protocol IDs: 0413, NCT01661335
7.	Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AML-11-001, NCT01334086
8.	Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Pro00031206, NCT01450826
9.	Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial Phase: No phase specified Type: Supportive care, Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: SENRI, NCT01344304
10.	Developing Individualized Strategies to Prevent Nausea and Vomiting Phase: No phase specified Type: Biomarker/Laboratory analysis, Supportive care Status: Approved-not yet active Age: 21 to 70 Sponsor: NCI, Other Protocol IDs: 1R01CA163074-01A1, 10831533, NCT01393288